Physician profile
Jarred E Marshak
NPI 1538417027
$1,406.43
in general payments reported to CMS, 2019-2025
15 companies · $612 in 2025
The $612 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2023: $179 · 2024: $381 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $297.53 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.21 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $198.69 | 2023-2025 | |
| Abbvie INC. | $192.50 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $141.34 | 2023-2024 | Voquezna |
| Pfizer INC. | $85.39 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.28 | 2024-2025 | Entyvio, Eohilia |
| Celgene Corporation | $51.52 | 2023-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $44.43 | 2019 | |
| Braintree Laboratories, INC. | $35.85 | 2019 | |
| Ardelyx, INC. | $23.29 | 2024 | Ibsrela |
| Janssen Biotech, INC. | $19.19 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $16.64 | 2025 | Lesionhunter |
| Allergan, INC. | $15.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarred Marshak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.